Disruptive technology for the treatment of hemophilia

July 10, 2017, Children's Hospital Los Angeles

An international team of hematologists including Guy Young, MD, of Children's Hospital Los Angeles, has found that in patients with hemophilia A with inhibitors, a novel therapy called emicizumab, decreases incidence of bleeding episodes by 87%. Results of this multicenter phase III study called HAVEN 1, will be presented at the International Society of Thrombosis and Hemostasis and published in the New England Journal of Medicine on July 10.

Individuals with A experience excessive bleeding and require prophylactic treatment with intravenously administered clotting factor usually 3 times each week. However, repeated administration of clotting factor can result in the development of antibodies, called inhibitors, that attack and destroy the necessary factor - making treatment of these patients very difficult.

Emicizumab, a novel monoclonal antibody, is given subcutaneously only once per week. According to Alan S. Wayne, MD, director of the Children's Center for Cancer and Blood Diseases, "This is a breakthrough for individuals with hemophilia A who no longer respond to conventional clotting therapies. The standard treatment for patients with hemophilia A and inhibitors has been to use medications called 'by-passing agents'. This new therapy is dramatically more effective at preventing bleeding. Additionally, in comparison to by-passing agents, emicizumab is easier to administer, requires less frequent dosing, and based on this study, appears to have an improved safety profile."

Guy Young, MD, director of the Hemostasis and Thrombosis Program and lead physician for study efforts at Children's Hospital Los Angeles explains further, "While the standard medications allow us to 'bypass' the need for Factor VIII, they don't do the job as efficiently or as well for these patients. Bleeding is harder to stop, and episodes last longer and do more damage to the patients. A patient treated with this had been in a wheelchair for three years because of joint damage from repeated bleeding incidents. Now, he's walking."

The study enrolled 109 males over the age of 12 with hemophilia A with inhibitors. Individuals treated with emicizumab experienced 87% fewer bleeds compared to untreated patients and 79% fewer bleeds compared to patients treated with bypassing agents. No anti-drug antibodies were detected.

"This is the most significant advancement I have seen during my 20 years working in the field of hemophilia," said Young, who is also a professor of Pediatrics at the Keck School of Medicine of USC and treats the most pediatric patients with hemophilia in California. "We've had families flying in from all over the country to get access to this medication."

Studies investigating the use of emicizumab in hemophilia A patients without are underway. This medication is only available to as part of a clinical trial but is currently being evaluated by the FDA.

Explore further: Long lasting anti-hemophilia factor safe in kids

Related Stories

Long lasting anti-hemophilia factor safe in kids

April 24, 2015
Children with hemophilia A require three to four infusions each week to prevent bleeding episodes, chronic pain and joint damage. The effect on quality of life can be significant, due to time and discomfort associated with ...

New findings offer hope for those with severe hemophilia

May 26, 2016
(HealthDay)—Two new studies could pave the way to major changes in how severe cases of hemophilia are treated. Both studies were published in the May 26 issue of the New England Journal of Medicine.

Study first to confirm effectiveness and safety of new treatment for hemophilia

November 2, 2011
An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events ...

Study suggests another look at common treatments for hemophilia

June 13, 2016
Families of children with severe hemophilia A may want to take a fresh look at treatment options from human plasma. A study published in the New England Journal of Medicine on May 26 showed that participants who received ...

To treat one rare blood disorder, scientists exploit another

October 27, 2016
For the nearly 400,000 individuals around the world with hemophilia A and hemophilia B—rare blood disorders that impair a person's ability to form clots to stop bleeding—relief may someday come from a treatment with similarities ...

Antibody for severe hemophilia a may reduce injections needed to prevent bleeding

December 1, 2015
An antibody engineered to prevent excessive bleeding in patients with severe hemophilia A may be safe and effective, and require fewer injections than existing options, according to a first-in-human study of the treatment ...

Recommended for you

Fabric imbued with optical fibers helps fight skin diseases

February 23, 2018
A team of researchers with Texinov Medical Textiles in France has announced that their PHOS-ISTOS system, called the Fluxmedicare, is on track to be made commercially available later this year. The system consists of a piece ...

Low-calorie diet enhances intestinal regeneration after injury

February 22, 2018
Dramatic calorie restriction, diets reduced by 40 percent of a normal calorie total, have long been known to extend health span, the duration of disease-free aging, in animal studies, and even to extend life span in most ...

Artificial intelligence quickly and accurately diagnoses eye diseases and pneumonia

February 22, 2018
Using artificial intelligence and machine learning techniques, researchers at Shiley Eye Institute at UC San Diego Health and University of California San Diego School of Medicine, with colleagues in China, Germany and Texas, ...

Gut microbes protect against sepsis—mouse study

February 22, 2018
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers ...

Fertility breakthrough: New research could extend egg health with age

February 22, 2018
Women have been told for years that if they don't have children before their mid-30s, they may not be able to. But a new study from Princeton University's Coleen Murphy has identified a drug that extends egg viability in ...

Therapy for muscular dystrophy-caused heart failure also improves muscle function in mice

February 22, 2018
Injections of cardiac progenitor cells help reverse the fatal heart disease caused by Duchenne muscular dystrophy and also lead to improved limb strength and movement ability, a new study shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.